InflaRx N.V.
NASDAQ:IFRX
| Market Cap (Intraday) | 85.17M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.40 |
| 50-Day MA | $1.56 |
| 200-Day MA | $2.30 |
InflaRx N.V. Stock, NASDAQ:IFRX
Winzerlaer Strasse 2, Jena, Thueringen 07745
Germany
Phone: +49.36.41.508180
Number of Employees: 66
Description
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.